← Back to all trials
Recruiting
NCT07314346
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Conditions: Healthy Volunteer Study
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 32
Sponsor: Atea Pharmaceuticals, Inc.
Location: Atea Study Site Hollywood Florida
Summary
Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Eligibility Criteria
Inclusion Criteria:
* Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug.
* Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/ m2.
* Willing to comply with the study requirements and to provide written informed consent.
Exclusion Criteria:
* Infected with hepatitis B virus, hepatitis C virus, HIV.
* Abuse of alcohol or drugs.
* Use of other investigational drugs within 28 days prior to Day -5.
* Concomitant use of prescription medications, or systemic over-the-counter medications (apart from methadone or buprenorphine/naloxone as assigned maintenance therapy).
* Other clinically significant medical conditions or laboratory abnormalities.
Source: ClinicalTrials.gov (NCT07314346). StuddyBuddy aggregates publicly available trial information.
